All In Biotech

Drug Trial Radar · NCT06876506

Identification of B Regulatory Cells by Flow Cytometry

Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jan 21, 2026

Primary completion

May 31, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Hull University Teaching Hospitals NHS TrustGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Health Education England, Wessex; University of Manchester
First posted
Mar 14, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients who are receiving routine allergen immunotherapy treatment. The primary question this study aims to answer is; 1). Are changes in blood B-regulatory cells associated with successful allergen immunotherapy treatment, and therefore do these changes suggest patients have developed a suitable level of allergen tolerance and reduction in their allergic symptoms upon re-exposure to the causal allergen. Patients will also be asked to complete quality of life questionnaire periodically throughout the study to determine if there are associations between variation in B-regulatory cell populations in blood and allergic symptoms experienced.

Conditions

  • Pollen Allergy
  • Venom Allergy

Interventions

  • VenepunctureDiagnostic test

    Whole blood flow cytometry analysis of T-/B-lymphocyte subsets, regulatory B cells and regulatory T cells. Serological detection (immunoassay) of allergen-specific IgE and IgG4

  • Allergen Specific ImmunotherapyDrug

    Test group receiving venom allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).

  • Allergen Specific ImmunotherapyDrug

    Test group receiving pollen allergen immunotherapy as part of standard and routine care pathway (treatment commencement NOT for study purposes, cohort selected of those who are routinely commencing treatment).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Utility of B regulatory cells as a biomarker of AIT treatment sucessTime frame: From enrolment to 1 year post commencing allergen-specific immunotherapy treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hull Teaching Hospital NHS Trust

    Hull, East Yorkshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.